Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine

Aliment Pharmacol Ther. 2018 Jan;47(1):141-142. doi: 10.1111/apt.14392.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal
  • Crohn Disease*
  • Humans
  • Infliximab
  • Precision Medicine
  • Tumor Necrosis Factor-alpha*

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab